Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02780869
Previous Study | Return to List | Next Study

HEMOBLAST Pivotal Clinical Investigation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02780869
Recruitment Status : Completed
First Posted : May 24, 2016
Results First Posted : November 7, 2018
Last Update Posted : December 27, 2018
Sponsor:
Information provided by (Responsible Party):
Biom'Up SA

Brief Summary:
The purpose of this prospective, randomized, controlled study is to evaluate the safety and efficacy of a new hemostatic device (HEMOBLAST™ Bellows) compared to a control device, absorbable gelatin sponge USP with thrombin.

Condition or disease Intervention/treatment Phase
Hemostasis Device: HEMOBLAST Bellows Device: Absorbable gelatin sponge, USP with thrombin Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 258 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Prospective, Randomized, Controlled, Multicenter, Pivotal, Clinical Investigation Evaluating the Safety and Efficacy of HEMOBLAST Bellows in Cardiothoracic, Abdominal, and Orthopedic Lower Extremity Surgeries
Actual Study Start Date : July 18, 2016
Actual Primary Completion Date : February 1, 2017
Actual Study Completion Date : March 27, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Investigational
HEMOBLAST Bellows
Device: HEMOBLAST Bellows
Active Comparator: Control
Absorbable gelatin sponge, USP with thrombin
Device: Absorbable gelatin sponge, USP with thrombin



Primary Outcome Measures :
  1. Proportion of Subjects Achieving Hemostasis [ Time Frame: Intraoperative, 6 Minutes Post-Application ]
    The proportion of subjects achieving hemostasis at 6 minutes post-hemostat application was calculated. Hemostasis was defined as a grade of 0 (None/Dry) on the Surface Bleeding Severity Scale, with additional grades, ranging from 1 (Minimal/Oozing) to 5 (Extreme/Gushing), considered a failure of hemostasis.


Secondary Outcome Measures :
  1. Product Preparation Time [ Time Frame: Intraoperative ]
    The average time from the opening of the package to the product being ready to use, measured in minutes and seconds.

  2. Proportion of Subjects Achieving Hemostasis [ Time Frame: Intraoperative, 3 Minutes Post-Application ]
    The proportion of subjects achieving hemostasis at 3 minutes post-hemostat application was calculated



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • • Subject is undergoing an elective open cardiothoracic, abdominal, or orthopedic lower extremity surgery;

    • Subject or an authorized legal representative is willing and able to give prior written informed consent for investigation participation;
    • Subject undergoing cardiothoracic surgery is not allergic to protamine; and
    • Subject is 21 years of age or older.

Exclusion Criteria:

  • • Subject is undergoing a laparoscopic, thoracoscopic, or robotic surgical procedure;

    • Subject is undergoing a neurologic surgical procedure;
    • Subject is undergoing a spinal surgical procedure;
    • Subject is undergoing an emergency surgical procedure;
    • Subject is pregnant, planning on becoming pregnant during the follow-up period, or actively breast-feeding;
    • Subject has a clinically significant coagulation disorder or disease, defined as a platelet count < 100,000 per microliter or International Normalized Ratio > 1.5 within 4 weeks of surgery;
    • Subject receiving intravenous heparin within 12 hours before surgery or oral Coumadin within 2 days before surgery;
    • Subject receiving antiplatelet medications within 5 days prior to surgery;
    • Subject undergoing abdominal or orthopedic lower extremity surgery receiving aspirin within 7 days prior to surgery;
    • Subject has an active or suspected infection at the surgical site;
    • Subject has had or has planned to receive any organ transplantation;
    • Subject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other component(s) of the hemostatic agent;
    • Subject has ASA classification of 5;
    • Subject has a life expectancy of less than 3 months;
    • Subject has a known psychiatric disorder, which in the opinion of the Principal Investigator, would preclude the subject from completing this clinical study;
    • Subject has a documented severe congenital or acquired immunodeficiency;
    • Subject has religious or other objections to porcine, bovine, or human components;
    • Subject in whom the investigational or control device will be used at the site of a valve replacement or repair;
    • Subject in whom the investigational or control device will be used at the site of a synthetic graft or patch implant;
    • Subject is currently participating or has participated in another clinical trial within the past 30 days and is receiving/has received an investigational drug, device, or biologic agent; and
    • Subject is not appropriate for inclusion in the clinical trial, per the medical opinion of the Principal Investigator.

Intraoperative Eligibility Criteria:

  • Subject does not have an active or suspected infection at the surgical site;
  • Subject undergoing cardiothoracic surgery with anticoagulation must have anticoagulation reversed prior to target bleeding site (TBS) identification and treatment;
  • Subject in whom the Investigator is able to identify a TBS for which any applicable conventional means for hemostasis are ineffective or impractical; and
  • Subject has a TBS with an SBSS score of 1, 2, or 3.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02780869


Locations
Layout table for location information
United States, Arizona
CORE Institute
Phoenix, Arizona, United States
United States, California
University of California Los Angeles
Los Angeles, California, United States
University of Southern California
Los Angeles, California, United States
Lotus Clinical Research
Pasadena, California, United States
United States, Florida
Miami Plastic Surgery
Miami, Florida, United States
United States, Hawaii
Queens Medical Center
Honolulu, Hawaii, United States
United States, Maryland
Suburban Hospital - Johns Hopkins Medicine
Bethesda, Maryland, United States, 20814
United States, Missouri
Washington University in St. Louis
Saint Louis, Missouri, United States
United States, New Hampshire
Dartmouth Hitchcock Medical Center
Hanover, New Hampshire, United States
United States, New York
Columbia University Medical Center / New York Presbyterian Hospital
New York, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
United States, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Duke University
Durham, North Carolina, United States
Hunstad Kortesis Center
Huntsville, North Carolina, United States
United States, Utah
Intermountain Liver Disease and Transplant Center
Murray, Utah, United States
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States
Spectrum Medical
Danville, Virginia, United States
Sponsors and Collaborators
Biom'Up SA
Investigators
Layout table for investigator information
Principal Investigator: William Chapman, MD Washington University School of Medicine
  Study Documents (Full-Text)

Documents provided by Biom'Up SA:
Study Protocol  [PDF] June 20, 2016
Statistical Analysis Plan  [PDF] July 1, 2016


Layout table for additonal information
Responsible Party: Biom'Up SA
ClinicalTrials.gov Identifier: NCT02780869     History of Changes
Other Study ID Numbers: ETC 2015-002
First Posted: May 24, 2016    Key Record Dates
Results First Posted: November 7, 2018
Last Update Posted: December 27, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Thrombin
Gelatin Sponge, Absorbable
Hemostatics
Coagulants